Cardiol Therapeutics Inc. Class A Common Shares (CRDL)
Cardiol Therapeutics Inc. is a Canadian biopharmaceutical company focused on developing and commercializing innovative therapies for cardiovascular diseases. The company specializes in utilizing cannabidiol (CBD) and other formulations to address inflammation and related conditions in the heart and vascular system. Its research aims to improve outcomes for patients with various cardiovascular disorders through targeted, potentially anti-inflammatory treatments.
Company News
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, ...